Schizophrenia is a complex psychiatric disorder where genetic, epigenetic, and
environmental factors play a role in disease onset, course of illness, and treatment outcome …

Aripiprazole was the first antipsychotic developed to possess agonist properties at
dopamine D2 autoreceptors, a groundbreaking strategy that presented a new vista for …

All antipsychotics bind to the dopamine D2 receptor. An “optimal” level of D2 receptor
blockade with antipsychotics is thought to ameliorate the positive symptoms of …

Schizophrenia is a major mental illness associated with profound disability. Current
treatments for schizophrenia (antipsychotics) all have a similar mechanism of action and are …

Schizophrenia is a severe neuropsychiatric disorder that affects approximately 0.5–1% of
the population. Response to antipsychotic therapy is highly variable, and it is not currently …

Diverse neuropsychiatric disorders present dysfunctional memory and no effective treatment
exits for them; likely as result of the absence of neural markers associated to memory …

Numerous genetic variants have been shown to be associated with antipsychotic response
and adverse effects of schizophrenia treatment. However, the clinical application of these …

Genetic risk for schizophrenia (SCZ) is determined by many genetic loci whose compound
biological effects are difficult to determine. We hypothesized that co-expression pathways of …

Second-generation antipsychotics are widely used for the treatment of schizophrenia.
Aripiprazole (ARI) is classified as a third-generation antipsychotic drug with a high affinity for …

Dopaminergic neurons projecting from the Substantia Nigra to the Striatum play a critical
role in motor functions while dopaminergic neurons originating in the Ventral Tegmental …